Ginkgo Bioworks Holdings, Inc. Class A Common Stock (DNA)

8.2000
+0.00 (0.00%)
NYSE · Last Trade: Nov 20th, 5:13 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Is Anthropic’s IPO a Good Reason to Buy Ginkgo Bioworks Right Now?fool.com
The AI developer's offering will give it a pile of cash that it might choose to spend on biomedical research automation.
Via The Motley Fool · November 18, 2026
Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investorsfool.com
Ginkgo's shift to physical data for AI labs is the thread tying its cost discipline to its hardware ambitions.
Via The Motley Fool · November 7, 2026
Ginkgo Bioworks Q3 Earnings Call Highlightsmarketbeat.com
Ginkgo Bioworks (NYSE:DNA) reported lower third-quarter revenue but narrowed its loss as restructuring-related expense cuts took hold, while executives highlighted new customers for its autonomous laboratory systems and cloud-based lab services. Revenue from continuing operations fell 6% year over
Via MarketBeat · November 7, 2026
Ginkgo Bioworks Holdings (NYSE:DNA) tumbles 15% in after-hours trading after Q1 revenue and earnings miss analyst estimateschartmill.com
Via Chartmill · May 7, 2026
Earnings Scheduled For November 6, 2025benzinga.com
Via Benzinga · November 6, 2025
Earnings Scheduled For August 7, 2025benzinga.com
Via Benzinga · August 7, 2025
Earnings Scheduled For May 6, 2025benzinga.com
Via Benzinga · May 6, 2025
Ginkgo Bioworks (DNA) Q3 2026 Earnings Call Transcriptfool.com
Ginkgo cut its quarterly loss 44% as it pivots to autonomous labs.
Via The Motley Fool · November 6, 2026
Cathie Wood Is Buying Archer Aviation Stock. Here's What History Says About Following Ark Into a Stock Down 62%.fool.com
Should investors follow Wood's lead with this eVTOL manufacturer?
Via The Motley Fool · October 29, 2026
This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubledfool.com
Eli Lilly is partnering with Ginkgo Bioworks on drug discovery.
Via The Motley Fool · October 5, 2026
Ginkgo Bioworks Q2 Earnings Call Highlightsmarketbeat.com
Ginkgo Bioworks (NYSE:DNA) reported second-quarter 2026 revenue of $20 million, down 48% from the year-earlier period, as the company continued to shift its focus toward autonomous laboratory systems, contract research services and related software. Chief Executive Officer Jason Kelly said the comp
Via MarketBeat · August 8, 2026
Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Thinkfool.com
A new biosecurity theme is emerging, and Palantir is leveraging it as an opportunity. Here's why that divide could matter for investors.
Via The Motley Fool · June 28, 2026
Ginkgo Bioworks Q1 Earnings Call Highlightsmarketbeat.com
Ginkgo Bioworks (NYSE:DNA) said it is sharpening its 2026 focus on autonomous laboratories after completing the divestiture of its biosecurity business and reporting lower year-over-year cash burn in the first quarter. Co-founder and CEO Jason Kelly said the company’s central objective remains “to
Via MarketBeat · May 9, 2026
Ginkgo Bioworks (DNA) Q1 2026 Earnings Transcriptfool.com
Ginkgo Bioworks (DNA) Q1 2026 Earnings Transcript
Via The Motley Fool · May 8, 2026
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.chartmill.com
Via Chartmill · February 27, 2026
Which stocks are moving on Friday?chartmill.com
Via Chartmill · February 27, 2026
What's going on in today's pre-market sessionchartmill.com
Via Chartmill · February 27, 2026
Wondering what's happening in today's after-hours session?chartmill.com
Via Chartmill · February 26, 2026
Moss, Microbes, and the Martian Dream: How Tiny Organisms Are Paving the Way for Off-World Colonies
The ambitious dream of humanity establishing permanent settlements beyond Earth is taking a significant leap forward, not through advanced robotics or colossal spacecraft, but with the humble power of space-hardy organisms, particularly moss and various extremophiles. These resilient life forms are emerging as foundational components for creating sustainable extraterrestrial ecosystems, offering a biologically integrated pathway [...]
Via TokenRing AI · November 24, 2025
Ginkgo Bioworks Stock Plummets Following Q3 Estimates Miss, Reaffirms FY2025 Outlook Below Consensusbenzinga.com
Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are trading lower on Friday. The company released its third-quarter financial results.
Via Benzinga · November 7, 2025
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · October 8, 2025
AI Unlocks Secrets of Intrinsically Disordered Proteins: A Paradigm Shift in Biomedical Design
A groundbreaking advancement in artificial intelligence has opened new frontiers in understanding and designing intrinsically disordered proteins (IDPs), a class of biomolecules previously considered elusive due to their dynamic and shapeless nature. This breakthrough, spearheaded by researchers at Harvard University and Northwestern University, leverages a novel machine learning method to precisely engineer IDPs with customizable [...]
Via TokenRing AI · October 6, 2025
5 Healthcare Stocks On Fire This Weekbenzinga.com
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.
Via Benzinga · August 21, 2025
Ginkgo Bioworks Holdings Inc (NYSE:DNA) Fits the Minervini Trend Template with Strong Technicals and High-Growth Momentumchartmill.com
Ginkgo Bioworks (DNA) meets Minervini Trend Template criteria with strong technicals, earnings growth, and momentum, making it a high-growth stock to watch.
Via Chartmill · August 1, 2025
Hewlett Packard Enterprise, Magnite, GMS And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · June 30, 2025